Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines
- 1 April 2014
- journal article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 14 (4) , 267-269
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospectsThe Lancet Infectious Diseases, 2014
- Progress in tuberculosis vaccine development and host-directed therapies—a state of the art reviewThe Lancet Respiratory Medicine, 2014
- Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort studyThe Lancet, 2014
- WHO's 2013 global report on tuberculosis: successes, threats, and opportunitiesThe Lancet, 2013
- Advances in the development of new tuberculosis drugs and treatment regimensNature Reviews Drug Discovery, 2013
- Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care testThe Lancet Infectious Diseases, 2013
- Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trialThe Lancet, 2013
- Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysisEuropean Respiratory Journal, 2012
- Sanatoria for drug-resistant tuberculosis: an outdated responseThe Lancet, 2012
- The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?The Lancet, 2012